Bavarian Nordic A/S (BV3)
XDUS
Closed
Aug 24, 2026
Day's Range
28.2252 wk Range
22.76Overview - BV3 - Bavarian Nordic A/S
Key Statistics
Valuation
Enterprise Value
-1.58B
P/E (Trailing)
‪1.61‬
PEG Ratio
‪-0.01‬
Price / Book
‪0.18‬
EV / EBITDA
‪-0.62‬
Profitability
Gross Margin
‪44.82%‬
Profit Margin
‪48.82%‬
Operating Margin
‪29.02%‬
Return on Assets
‪9.19%‬
Return on Equity
‪10.68%‬
Ownership
Shares Outstanding
77.14M
Price stats
50-Day Avg
‪24.19‬
200-Day Avg
‪25.09‬
Peers - BV3 - Bavarian Nordic A/S
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- BV3XDUSBavarian Nordic A/S-14.49%52-week change1.57P/E (Trailing)‪48.82%‬Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+86.32%52-week change-2.62P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.37%52-week change-46.21P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.66%52-week change-29.85P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.20%52-week change-22.50P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.55%52-week change—P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.54%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - BV3 - Bavarian Nordic A/S
About
Bavarian Nordic A/S is a Danish biotechnology company specializing in the research, development, manufacturing, and commercialization of innovative vaccines based on viral vector technologies. Headquartered in Hellerup, Denmark, with manufacturing facilities in Denmark and Switzerland, and R&D sites in Germany plus…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
